Considering that CML and TKI therapy induce changes in phenotype and function of immune cells (10–15), we performed extended immunophenotyping of NKT-like cells, including functional tests (degranulation and IFN-γ production), maturation, activation, and migration status markers and also detailed analysis of NKG2 family receptors, NCRs, NKp80 and immune checkpoints (ICP) expression on NKT-like cells from CML patients treated with tyrosine kinase inhibitors. Here, KLRC1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.